Nipah Open Library

A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease

Revision as of 02:17, 7 February 2026 by Nhmkerala (talk | contribs) (Created paper page - 2026-02-07T07:47:16.392237)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Authors: Stephanie L. Foster, Courtney Woolsey, Viktoriya Borisevich, Krystle N. Agans, Abhishek N. Prasad, Joan B. Geisbert, Natalie S. Dobias, Karla A. Fenton, Robert W. Cross, Thomas W. Geisbert, Daniel J. Dee

Year: 2024

Journal: Not specified in the text

DOI: 10.xxxx/xxxxx or null (not specified in the text)

PMID: PMID or null (not specified in the text)

Summary

The paper discusses a study using a recombinant vesicular stomatitis virus (rVSV) vaccine to protect nonhuman primates from lethal Nipah virus disease, with protection observed in monkeys vaccinated 7 days prior to NiV exposure and 67% of animals vaccinated 3 days before challenge.

Key Findings

  • Recombinant VSV-ΔGNiVBG vaccine protects nonhuman primates against lethal Nipah virus disease
  • Protection correlated with natural killer cell and cytotoxic T cell transcriptional signatures

Methodology

  • Study Type: Experimental/Vaccine trial
  • Sample Size: African green monkeys (number not specified)
  • Geographic Focus: Not specified in the text
  • Time Period: 3 or 7 days after vaccination and NiV challenge

Topics

Virology, Vaccine development

Relevance

The study demonstrates the potential utility of rVSV-based vaccines in rapidly protecting humans against Nipah virus infection, which could be crucial for controlling outbreaks

Source

View the entire paper: File:Pnas.202200065.pdf

Retrieved from "https://nipahlib.phenomi.co/index.php?title=A_recombinant_VSV-vectored_vaccine_rapidly_protects_nonhuman_primates_against_lethal_Nipah_virus_disease&oldid=357"